Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. Th...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/7/617 |
| _version_ | 1797528699593031680 |
|---|---|
| author | Servando E. Marron Lucia Tomas-Aragones Carlos A. Moncin-Torres Manuel Gomez-Barrera Francisco Javier Garcia-Latasa de Aranibar |
| author_facet | Servando E. Marron Lucia Tomas-Aragones Carlos A. Moncin-Torres Manuel Gomez-Barrera Francisco Javier Garcia-Latasa de Aranibar |
| author_sort | Servando E. Marron |
| collection | DOAJ |
| description | Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8–89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6–10); HADS median (range) total score = 13 (5–21); DLQI mean score = 16 (2–27); EQ-5D-3L median (range) = 57 (30–99). At week-52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0–17.1), HADS total score median (range) = 2 (0–10) and improved quality of life EQ-5D-3L median (range) = 89 (92–60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile. |
| first_indexed | 2024-03-10T10:03:06Z |
| format | Article |
| id | doaj.art-e60339a79bcf40f9bd118133c12f2c48 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T10:03:06Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-e60339a79bcf40f9bd118133c12f2c482023-11-22T01:48:33ZengMDPI AGLife2075-17292021-06-0111761710.3390/life11070617Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks ResultsServando E. Marron0Lucia Tomas-Aragones1Carlos A. Moncin-Torres2Manuel Gomez-Barrera3Francisco Javier Garcia-Latasa de Aranibar4Dermatology Department, University Hospital Miguel Servet, Aragon Psychodermatogy Research Group (GAI+PD), Paseo de Isabel la Catolica 1-3, 50009 Zaragoza, SpainPsychology Department, University of Zaragoza, Aragon Psychodermatology Research Group (GAI+PD), c/Pedro Cerbuna 12, 50009 Zaragoza, SpainPharmacy Department, Royo Villanova Hospital, Avda. San Gregorio 30, 50015 Zaragoza, SpainHealth Sciences Faculty, San Jorge University, Zaragoza, Autovia Mudejar, Km 299, Villanueva de Gallego, 50830 Zaragoza, SpainDermatology Department, Royo Villanova Hospital, Aragon Psychodermatology Research Group (GAI+PD), Avda. San Gregorio 30, 50015 Zaragoza, SpainDupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8–89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6–10); HADS median (range) total score = 13 (5–21); DLQI mean score = 16 (2–27); EQ-5D-3L median (range) = 57 (30–99). At week-52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0–17.1), HADS total score median (range) = 2 (0–10) and improved quality of life EQ-5D-3L median (range) = 89 (92–60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile.https://www.mdpi.com/2075-1729/11/7/617atopic dermatitispatient reported outcome measuresdupilumabquality of lifesatisfactionefficacy |
| spellingShingle | Servando E. Marron Lucia Tomas-Aragones Carlos A. Moncin-Torres Manuel Gomez-Barrera Francisco Javier Garcia-Latasa de Aranibar Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results Life atopic dermatitis patient reported outcome measures dupilumab quality of life satisfaction efficacy |
| title | Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results |
| title_full | Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results |
| title_fullStr | Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results |
| title_full_unstemmed | Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results |
| title_short | Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results |
| title_sort | patient reported outcome measure in atopic dermatitis patients treated with dupilumab 52 weeks results |
| topic | atopic dermatitis patient reported outcome measures dupilumab quality of life satisfaction efficacy |
| url | https://www.mdpi.com/2075-1729/11/7/617 |
| work_keys_str_mv | AT servandoemarron patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults AT luciatomasaragones patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults AT carlosamoncintorres patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults AT manuelgomezbarrera patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults AT franciscojaviergarcialatasadearanibar patientreportedoutcomemeasureinatopicdermatitispatientstreatedwithdupilumab52weeksresults |